Science & Enterprise subscription

Follow us on Twitter

  • A drug targeting immune system enzymes used as a skin cream is shown in a clinical trial to reverse effects of viti…
    about 1 hour ago
  • New post on Science and Enterprise: Topical Immune Drug Reverses Skin Disease #Science #Business
    about 1 hour ago
  • Medical researchers and data scientists are using artificial intelligence, or A.I., to diagnose children’s intestin…
    about 21 hours ago
  • New post on Science and Enterprise: A.I. Harnessed to Diagnose Children’s Gut Diseases #Science #Business
    about 21 hours ago
  • University engineers and chemists are creating a more efficient material for separating carbon dioxide from emissio…
    about 1 day ago

Please share Science & Enterprise

Biomarker Diagnostics Company Gains $40M in Venture Funding

Loose bills of multiple denominations (borman818)Astute Medical Inc. in San Diego, a developer of biomarker-based medical diagnostics, says it completed $40.4 million in series C venture financing, the third cycle of funding after initial start-up. The funding round was led by MPM Capital and included new investor Kaiser Permanente Ventures, as well as existing investors De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development Corporation.

Astute Medical identifies and validates protein biomarkers that can be used for diagnosing diseases, particularly with labratory (in vitro) tests. The company’s current interests include tests involving abdominal pains, acute coronary syndromes, cerebrovascular injury (e.g., stroke), kidney injury, and sepsis.

The company plans to use the proceeds from the round to begin commercializing its first product, as well as advance and expand its research, development, and validation of biomarker-based lab tests. Details about its first commercial product were not disclosed.

Astute Medical was founded in 2007 by former executives in the diagnostics company Biosite Inc.  The company completed its series A funding round in May 2008, with $6.2 million led by DeNovo Ventures. Its series B round, was divided into two segments: $26.5 million in May 2010, and $13 million in March 2011.

Read more:

Hat tip: Fortune/Term Sheet

Photo: borman818/Flickr

*     *     *

Please share Science & Enterprise ...

Comments are closed.